

CORRECTION

Open Access



Correction: GlucoMedix[®], an extract of *Stevia rebaudiana* and *Uncaria tomentosa*, reduces hyperglycemia, hyperlipidemia, and hypertension in rat models without toxicity: a treatment for metabolic syndrome

León F. Villegas Vilchez^{1,2}, Julio Hidalgo Ascencios² and Thomas P. Dooley^{3*} 

Correction: *BMC Complement Med Ther* 22, 62 (2022)
<https://doi.org/10.1186/s12906-022-03538-9>

Following publication of the original article [1], the authors reported an error in Table 8 and Fig. 8.

The Table 8 reported for the glucose levels (Alloxan-induced) of GlucoMedix[®] treatments was incorrect. However, the correct data set reveals that the results are similar to those reported. The percentage of the chemically induced maximum level minus the uninduced level at 28 days (as displayed in Fig. 8) is 62.0 % at 250 mg/kg (vs 36.4 % as reported), 16.3 % at 500 mg/kg (vs 13.5 % as reported), and 0.8 % at 1,000 mg/kg (vs -2.6 % as reported), and the Glibenclamide 10 mg/kg positive control should be -1.2 % (vs -5.6 % as reported). Thus, the IC₅₀ value for glucose levels with GlucoMedix[®] is between 250 and 500 mg/kg (vs < 250 mg/kg as reported). Furthermore, the number of animals per group for the glucose and lipid profile experiments was five (vs seven as reported).

The original article [1] has been updated.

Author details

¹Department of Cellular and Molecular Sciences, Section of Pharmaceutical Sciences, Faculty of Sciences and Philosophy, Universidad Peruana Cayetano Heredia, Lima, Peru. ²Quality Control Service, Research and Development Laboratories, Universidad Peruana Cayetano Heredia, Lima, Peru. ³Research and Development, LivFul Inc, Cheshire, UK.

Published online: 27 August 2022

Reference

1. Villegas Vilchez LF, Ascencios JH, Dooley TP. GlucoMedix[®], an extract of *Stevia rebaudiana* and *Uncaria tomentosa*, reduces hyperglycemia, hyperlipidemia, and hypertension in rat models without toxicity: a treatment for metabolic syndrome. *BMC Complement Med Ther.* 2022;22:62. <https://doi.org/10.1186/s12906-022-03538-9>.

The original article can be found online at <https://doi.org/10.1186/s12906-022-03538-9>.

*Correspondence: tom@tomdooley.org; tdooley@livful.com

³ Research and Development, LivFul Inc, Cheshire, UK

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Table 8 Effect of GlucoMedix® on glucose concentrations in alloxan-induced hyperglycemic rats

Group/dose (mg/kg)	Glucose (mg/dl)					
	BASAL	0days	7days	14days	21days	28days
Control (uninduced)	90.3 ± 1.49	92.0 ± 1.63 &&	93.3 ± 2.36 &&	94.3 ± 2.43 &&	96.2 ± 2.41 &&	98.5 ± 2.36 &&
Negative Control (induced)	92.7 ± 4.50	495.7 ± 20.62 **	528.2 ± 20.42 **	545.7 ± 15.91 **	566.3 ± 12.34 **	579.0 ± 11.87 **
Glibenclamide 10	90.3 ± 2.34	500.0 ± 17.03 **	287.8 ± 18.76 *&	137.5 ± 8.78 *&&	107.3 ± 4.55 &&	92.7 ± 1.97 &&
GlucoMedix 250	90.2 ± 3.89	509.7 ± 13.83 **	482.5 ± 10.90 **&&	448.7 ± 12.49 **&	418.8 ± 16.10 **&	396.5 ± 13.38 **&
GlucoMedix 500	94.3 ± 3.77	512.5 ± 14.63 **	324.2 ± 17.06 **&	268.2 ± 15.83 *&	207.2 ± 2.54 *&&	177.0 ± 6.71*&&
GlucoMedix 1000	93.3 ± 3.33	501.5 ± 9.54 **	305.0 ± 8.00 **&	216.3 ± 4.93 *&&	146.2 ± 13.47 *&&	102.2 ± 4.02 &&

Values are expressed as mean ± SD. n= 5. Statistical significance was * p<0.05, ** p<0.001 compared to control group (uninduced); & p<0.05, && p<0.001 compared to negative control group (induced)




Fig. 8 Dose response for oral GlucoMedix® in rat models. GlucoMedix® (250, 500, 1000 mg/kg) treatment effects, expressed as the percentage of the chemically induced maximum minus the uninduced baseline; glucose at 28 days; cholesterol and triglycerides at 21 days; systolic, diastolic, and mean BP at 28 days